It has been a year since the release of Leclaza

Cumulative sales exceed 10 billion won

6.9 billion won in the first half of this year

Korea's first new anti-cancer drug is expected to generate 10 billion won in annual sales.

 

Leclaza, a new anti-cancer drug developed by Yuhan Corporation, surpassed 10 billion won in cumulative sales within a year of its release in Korea.

 

It showed a smooth move in the early stages of its release and predicted that it would surpass 10 billion won in annual sales for the first time among new anticancer drugs developed in Korea.

 

According to IQVIA, Leclaza recorded 6.9 billion won in sales in the first half of last year.

 

After recording 3.2 billion won in the first quarter, sales expanded to 3.7 billion won in the second quarter.

 

Leclaza is a non-small cell lung cancer treatment approved as the 31st new drug developed in Korea in January last year.

 

Patients with local progressive or metastatic non-small cell lung cancer who developed T790M resistance after administration of the first and second generation epithelial cell growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).

 

It acts as a mechanism to suppress the growth and growth of lung cancer cells by interfering with signal transmission involved in lung cancer cell growth.

 

Leclaza entered the prescription market in earnest with the listing of health insurance benefits in July last year.

 

It earned 4.1 billion won in sales in the second half of last year alone.

 

The first sales of 1.5 billion won occurred in the third quarter of last year, and 2.6 billion won worth of sales were sold in the fourth quarter.

 

Until the second quarter of this year, Leclaza's cumulative sales amounted to 11 billion won.

 

It surpassed 10 billion won in cumulative sales within a year of its release.

 

If this trend continues, Leclaza is likely to surpass 10 billion won in annual sales in its second year of release.

 

Leclaza's early performance in the release is considered a smooth start.

 

Anti-cancer drugs, which are usually used in large medical institutions, can be prescribed after passing the drug commitee, so it takes a considerable amount of time for sales to occur in the early stages of release.

 

Domestic developed anticancer drugs approved before Leclaza include Ilyang Pharmaceutical Supect, Donghwa Pharmaceutical Millican, Chong Kun Dang Camtobell, Samsung Pharmaceutical Riavax, and Hanmi Pharmaceutical Olita.

 

None of these products exceed 10 billion won in annual sales.

 

Leclaza passed the Pharmacist Committee of 80 medical institutions within a year of the launch of the salary, and it is expected to grow more steeply in the second half of the year.

 

Leclaza's recent excellent clinical results are also the background of optimism about market settlement.

 

Recently released clinical results of Leclaza showed a meaningful figure that the median overall survival period was 38.9 months.

 

The overall survival rate of the Leclaza-administered group was confirmed to be ▲ 90% of12 months, ▲74% of 24 months, ▲53 % of 36 months.

 

Yuhan Corporation has secured a total of $150 million in technology fees through Leclaza.

 

In November 2018, Leclaza was technically exported to Janssen Biotech, Inc., and at that time, it received a down payment of $50 million, which was not obligated to return.

 

Yuhan Corporation received $35 million in milestones from Janssen in April 2020.

 

At the time, Janssen began clinical trials of Amivantamab and Leclaza combination therapy, and provided additional milestones to Yuhan Corporation.

 

In November 2020, Janssen paid an additional $65 million in milestones to Yuhan Corporation when it began recruiting subjects for the clinical trial.